Associations between individual depressive symptoms and immunometabolic characteristics in major depression.


Journal

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
ISSN: 1873-7862
Titre abrégé: Eur Neuropsychopharmacol
Pays: Netherlands
ID NLM: 9111390

Informations de publication

Date de publication:
06 2023
Historique:
received: 15 11 2022
revised: 03 03 2023
accepted: 07 03 2023
medline: 29 5 2023
pubmed: 27 3 2023
entrez: 26 3 2023
Statut: ppublish

Résumé

Inflammation and metabolic dysregulations are likely to underlie atypical, energy-related depressive symptoms such as appetite and sleep alterations. Indeed, increased appetite was previously identified as a core symptom of an immunometabolic subtype of depression. The aim of this study was 1) to replicate the associations between individual depressive symptoms and immunometabolic markers, 2) to extend previous findings with additional markers, and 3) to evaluate the relative contribution of these markers to depressive symptoms. We analyzed data from 266 persons with major depressive disorder (MDD) in the last 12 months from the German Health Interview and Examination Survey for Adults and its mental health module. Diagnosis of MDD and individual depressive symptoms were determined by the Composite International Diagnostic Interview. Associations were analyzed using multivariable regression models, adjusting for depression severity, sociodemographic/behavioral variables, and medication use. Increased appetite was associated with higher body mass index (BMI), waist circumference (WC), insulin, and lower high-density lipoprotein. In contrast, decreased appetite was associated with lower BMI, WC, and fewer metabolic syndrome (MetS) components. Insomnia was associated with higher BMI, WC, number of MetS components, triglycerides, insulin, and lower albumin, while hypersomnia was associated with higher insulin. Suicidal ideation was associated with higher number of MetS components, glucose, and insulin. None of the symptoms were associated with C-reactive protein after adjustment. Appetite alterations and insomnia were most important symptoms associated with metabolic markers. Longitudinal studies should investigate whether the candidate symptoms identified here are predicted by or predict the development of metabolic pathology in MDD.

Identifiants

pubmed: 36966710
pii: S0924-977X(23)00050-0
doi: 10.1016/j.euroneuro.2023.03.007
pii:
doi:

Substances chimiques

Insulins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

25-40

Informations de copyright

Copyright © 2023 Elsevier B.V. and ECNP. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest CO reports honoraria for lectures and/or scientific advice from Ferring, Janssen, Lundbeck, SAGE Therapeutics, Fortbildungskolleg, Limes Klinikgruppe, and Medical Tribune. SMG reports honoraria from Celgene and Hexal and research funding from Biogen. All other authors declare no potential conflict of interest.

Auteurs

Woo Ri Chae (WR)

Charité - Universitätsmedizin Berlin, Department of Psychiatry and Neurosciences, Campus Benjamin Franklin, Berlin, Germany. Electronic address: woo-ri.chae@charite.de.

Jens Baumert (J)

Robert-Koch Institute, Department of Epidemiology and Health Monitoring, Berlin, Germany.

Julia Nübel (J)

Robert-Koch Institute, Department of Epidemiology and Health Monitoring, Berlin, Germany.

Jelena Brasanac (J)

Charité - Universitätsmedizin Berlin, Department of Psychiatry and Neurosciences, Campus Benjamin Franklin, Berlin, Germany.

Stefan M Gold (SM)

Charité - Universitätsmedizin Berlin, Department of Psychiatry and Neurosciences, Campus Benjamin Franklin, Berlin, Germany; Charité - Universitätsmedizin Berlin, Medical Department, Section Psychosomatic Medicine, Hindenburgdamm 30, 12203 Berlin, Germany; Institute of Neuroimmunology and Multiple Sclerosis (INIMS), Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Ulfert Hapke (U)

Robert-Koch Institute, Department of Epidemiology and Health Monitoring, Berlin, Germany.

Christian Otte (C)

Charité - Universitätsmedizin Berlin, Department of Psychiatry and Neurosciences, Campus Benjamin Franklin, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH